{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T07:12:41Z","timestamp":1689750761093},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1097\/md.0000000000010416","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T10:29:19Z","timestamp":1523442559000},"page":"e0416","source":"Crossref","is-referenced-by-count":2,"title":["A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection"],"prefix":"10.1097","volume":"97","author":[{"given":"Chen","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JinHua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-74-20210309","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"R2-74-20210309","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","article-title":"Evolving epidemiology of hepatitis C virus","volume":"17","author":"Lavanchy","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"R3-74-20210309","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00535-007-2064-6","article-title":"The epidemiology of hepatitis C infection in the United States","volume":"42","author":"Rustgi","year":"2007","journal-title":"J Gastroenterol"},{"key":"R4-74-20210309","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"R5-74-20210309","first-page":"CD011644","article-title":"Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis","volume":"3","author":"Kalafateli","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R6-74-20210309","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hep.21043","article-title":"Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study","volume":"43","author":"Wiegand","year":"2006","journal-title":"Hepatology"},{"key":"R7-74-20210309","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/hep.26991","article-title":"Acute hepatitis C: a 24-week course of pegylated interferon \u03b1-2b versus a 12-week course of pegylated interferon \u03b1-2b alone or with ribavirin","volume":"59","author":"Santantonio","year":"2014","journal-title":"Hepatology"},{"key":"R8-74-20210309","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C 2016.","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"R9-74-20210309","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S2468-1253(17)30003-1","article-title":"Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial","volume":"2","author":"Rockstroh","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R10-74-20210309","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1473-3099(16)30408-X","article-title":"Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study","volume":"17","author":"Deterding","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R11-74-20210309","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/gutjnl-2016-312444","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort","volume":"65","author":"Welzel","year":"2016","journal-title":"Gut"},{"key":"R12-74-20210309","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jhep.2013.06.028","article-title":"A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection","volume":"59","author":"Beinhardt","year":"2013","journal-title":"J Hepatol"},{"key":"R13-74-20210309","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/hep.29611","article-title":"Should we treat acute hepatitis C? A decision and cost-effectiveness analysis","volume":"67","author":"Bethea","year":"2017","journal-title":"Hepatology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000010416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:03:56Z","timestamp":1620961436000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201804130-00074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":13,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000010416","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}